Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, coul...

Source: Lipids in Health and Disease - January 12, 2021 Category: Lipidology Authors: Yihai Liu, Jiamin Xu, Mingyue Wu, Biao Xu and Lina Kang Tags: Research Source Type: research